DERMOVATE 0.05% 25 GM CREAM

* Dermovate (Clobetasol Propionate 0.05%) cream 25 g.

* Composition: Each 100 gm contains:

  Clobetasol 17 propionate 0.054 gm equivalent to Clobetasol propionate 0.05 gm.

* Therapeutic indications:

– Psoriasis (excluding widespread plaque psoriasis).

– Recalcitrant eczemas.

– Lichen planus.

– Discoid lupus erythematosus and other skin conditions which do not respond satisfacorily to less active steroids.

* Dosage and administration:

Apply sparingly to the affected area once or twice daily. Therapy should be discontinued when control is achieved. Treatment should not be continued for more than 4 weeks without patient’s condition being reviewed. Repeated short courses of Dermovate may be used to control exacerbations. If continuous steroid treatment is necessary, a less potent preparation should be used. In very resistant lesions, especially where there is hyperkeratosis, the anti-inflammatory effect of Dermovate can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response. Thereafter improvement can be usually be maintained by application without occlusion.

* Contra-indications:

– Rosacea.

– Acne vulgaris.

– Perioral dermatitis.

– Perianal and genital pruritus.

– Primary cutaneous viral infections (e.g., herpes simplex, chickenpox).

– Hypersensitivity to the preparation.

– The use of Dermovate skin preparations is not indicated in the treatment of primary infected skin lesions caused by infection with fungi or bacteria; dermatoses in children ubder one year of age, including dermatitis and napkin eruptions.

* For external use only.

* Store at room temperature.

* Manufactured by: SmithKline Beecham (SB), Haram – Giza. For: GlaxoSmithKline (gsk) S.A.E. – Egypt.

  Under License from: Glaxo Wellcome – UK.

  DERMOVATE is a trade mark of the GlaxoSmithKline group of companies.